Clinical trials: Cerebral Ischemic Events
Giant Cell Arteritis, Neurovascular Disorder
Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement
A French multicenter randomised and placebo-controlled study recruiting patients who present neurovascular involvement related to GCA (> 60 years) with symptomatic (stroke) or asymptomatic forms.
- Trial name
- TOGIAC (NCT04888221)
- Testing
- Tocilizumab
- Where
- France
- Volunteers
- 66 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Moyamoya Disease, Ischemic Cerebral Infarction
NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events
An extracranial-to-intracranial (EC-IC) revascularization is the most widely used treatment to improve cerebral perfusion in patients with moyamoya disease (MMD), and it has been shown to reduce the risk of subsequent stroke and…
- Conditions
- Moyamoya Disease, Ischemic Cerebral Infarction, Ischemic Stroke, Ischemic Cerebrovascular Accident
- Trial name
- NICE-MMD (NCT04205578)
- Testing
- dl-3-n-butylphthalide (NBP), Normal Saline 0.9% Infusion Solution
- Where
- 2 sites in China
- Volunteers
- 450 people
- Sponsor
- yuanli Zhao
Polyvascular Disease, Atherosclerosis
Clinical Register Studying the therApeutic Patient Population With Multifocal Atherosclerosis
Аn international, multicenter, non-interventional real-life clinical practice Register studying the Actual therapeutic patient population with Multifocal Atherosclerosis in the Russian Federation and Eurasian countries
- Conditions
- Polyvascular Disease, Atherosclerosis, Atherosclerosis Generalized, Cardiovascular Diseases
- Trial name
- KAMMA (NCT05189847)
- Where
- Russia
- Volunteers
- 3,059 people
- Sponsor
- Eurasian Association of Therapists
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-1 (NCT01975376)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,745 sites in United States, Argentina and 34 more
- Volunteers
- 16,784 people
- Sponsor
- Pfizer
Ischemic Stroke
The Prevalence of a Low Ankle-Brachial Index in Acute Cerebral Ischemia.
Aim of the study is assessment the prevalence of the low ankle-brachial index (ABI) defined less than or equal 0.9 in patients with acute cerebral ischemic event (stroke or transient ischemic attack) and determinate the…
- Trial name
- NCT03948399
- Testing
- Duplex scanning of carotid arteries, ABI measurement
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Jan Biziel University Hospital No 2 in Bydgoszcz
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-2 (NCT01975389)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,595 sites in United States, Argentina and 33 more
- Volunteers
- 10,564 people
- Sponsor
- Pfizer
Cardiovascular Event, Parkinson Disease
Cardiovascular Events in Parkinson's Disease Patients
Cardiovascular (CV) disease is a common comorbidity of Parkinson's disease (PD). The background incidence rate of CV events in a levodopa-treated PD population was assessed to better understand these comorbidities in the PD…
- Trial name
- NCT01545856
- Testing
- levodopa
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Hypotension, Postoperative Complications
Biomarkers, Blood Pressure, BIS: Risk Stratification/Management of Patients at Cardiac Risk in Major Noncardiac Surgery
Major adverse cardiovascular events (MACE) are a leading cause of serious complications and death following major noncardiac surgery.
- Conditions
- Hypotension, Postoperative Complications, Acute Coronary Syndrome, Heart Failure
- Trial name
- BBB (NCT02533128)
- Testing
- Liberal blood pressure management, Tight blood pressure management
- Where
- Switzerland
- Volunteers
- 458 people
- Sponsor
- Miodrag Filipovic, Prof. Dr. med.
Cardiovascular Disease, Peripheral Arterial Disease
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
The primary aim is to assess the effects of raising HDL cholesterol (the good type) with extended release niacin/laropiprant 2g (previously known as MK-0524A) versus matching placebo on the risk of heart attack or coronary death…
- Conditions
- Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus, Coronary Heart Disease
- Trial name
- HPS2-THRIVE (NCT00461630)
- Testing
- ER niacin/laropiprant, simvastatin, ezetimibe/simvastatin
- Where
- United Kingdom
- Volunteers
- 25,673 people
- Sponsor
- University of Oxford
Ultrasonography, Carotid Stenosis
Prognostic Value of Carotid CEUS in Acute Ischemic Stroke Patients
Contrast-enhanced ultrasound(CEUS) of carotid artery plaque is a novel method that enabled direct visualization of neovessels in the vulnerable plaque.
- Conditions
- Ultrasonography, Carotid Stenosis, Ischemic Stroke
- Trial name
- NCT03283306
- Where
- South Korea
- Volunteers
- 667 people
- Sponsor
- Seoul National University Hospital
Cerebrovascular Event, Stent Stenosis
Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation
APICES trial is an investigator-initiated, multicenter, multicenter, randomized, double-blind, placebo-controlled clinical trial that plans to enroll 396 patients with a 1-year follow-up, including a neurovascular imaging…
- Conditions
- Cerebrovascular Event, Stent Stenosis, Ischemic Stroke, Hemorrhagic Stroke
- Trial name
- NCT06308952
- Testing
- Atorvastatin 20mg
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Duan Chuanzhi
Brain Infarction, Transient Ischemic Attack
Aortic Arch Related Cerebral Hazard Trial (ARCH)
The ARCH is a controlled trial with a sequential design and with a prospective, randomized, open-label, blinded-endpoint (PROBE) methodology.
- Conditions
- Brain Infarction, Transient Ischemic Attack, Embolism
- Trial name
- ARCH (NCT00235248)
- Testing
- Warfarin, Clopidogrel-aspirin
- Where
- 2 sites in Australia, France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Infection, Acute Coronary Syndrome
Association Between Levels of D-Dimer, Fibrinogen and PAI-1 in Elderly Patients With Infection and Occurrence of Cardio- and Cerebro-vascular Disease After Discharge
The association between the levels of d-dimer, fibrinogen and PAI-1 in plasma of elderly patients admitted to internal medicine departments because of infection and the occurrence of cardio- and cerebro-vascular disease after…
- Conditions
- Infection, Acute Coronary Syndrome, Cerebrovascular Disease
- Trial name
- NCT00512603
- Volunteers
- 52 people
- Sponsor
- Wolfson Medical Center
Ischemic Stroke, Mild
ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)
The purpose of this study is to investigate the safety and efficacy of rhPro-UK (35mg) versus standard medical treatment in acute mild ischemic stroke within 4.5 hours of symptom onset.
- Conditions
- Ischemic Stroke, Mild, Thrombosis
- Trial name
- PUMICE (NCT05507645)
- Testing
- Recombinant Human Prourokinase for Injection (rhPro-UK), standard medical treatment
- Where
- 89 sites in China
- Volunteers
- 1,446 people
- Sponsor
- Beijing Tiantan Hospital
Ischemic Stroke
Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.
Aspirin is the only anti-platelet medication used at the acute phase of ischemic stroke. The investigators would like to study laboratory effect of the first oral 300 mg dose of aspirin, given at hospital, after an ischemic…
- Trial name
- Aspirin (NCT01375400)
- Testing
- Aspirin, blood sample
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Central Hospital, Nancy, France
ANCA-associated Primary Necrotizing Vasculitides
Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides
The purpose of this study is to assess whether rosuvastatin could reduce the subclinical markers of atherosclerosis and the incidence of major cardiovascular events in patients with primary necrotizing vasculitides.
- Trial name
- STATVAS (NCT02117453)
- Testing
- Rosuvastatin
- Where
- France
- Volunteers
- 121 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myocardial Infarction, Cardiac Arrest
Troponin-T for Detection of Perioperative Cardiovascular Events
We will conduct a prospective cohort study evaluating the incidence of and optimal risk estimation model for major perioperative cardiovascular events in consecutive patients undergoing noncardiac surgery at the 'Herlev…
- Trial name
- VISION-pilot (NCT00443989)
- Where
- 2 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Ischemic Stroke, Blood Pressure
Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients
Elevated blood pressure (BP) consists of a major public health concern especially in low and middle income countries. Besides being a highly prevalent condition, it is also a risk factor for several major cardiovascular events…
- Conditions
- Ischemic Stroke, Blood Pressure, Cognitive Impairment, Vascular Diseases
- Trial name
- OPTIMAL Stroke (NCT04036409)
- Testing
- Intensive Control of Systolic Blood Pressure (SBP), Standard control of Systolic Blood Pressure (SBP)
- Where
- 30 sites in Brazil
- Volunteers
- 4,368 people
- Sponsor
- Hospital Israelita Albert Einstein
Death, Myocardial Infarction
A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients
This study evaluates whether achieving 25-hydroxyvitamin D (25[OH] Vit D) levels (>40 ng/mL) among myocardial infarction patients will result in a reduction of cardiovascular-related adverse events.
- Conditions
- Death, Myocardial Infarction, Cerebral Vascular Accident, Heart Failure Hospitalization
- Trial name
- TARGET-D (NCT02996721)
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 634 people
- Sponsor
- Intermountain Health Care, Inc.
Vascular Death, Myocardial Infarction
Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)
The investigators' study has 4 primary objectives. Among patients undergoing noncardiac surgery the investigators will determine: (1) the incidence of major perioperative vascular events; (2) the optimal clinical model to predict…
- Conditions
- Vascular Death, Myocardial Infarction, Cardiac Arrest, Stroke
- Trial name
- VISION (NCT00512109)
- Where
- 8 sites in Brazil, Canada and 5 more
- Volunteers
- 40,060 people
- Sponsor
- McMaster University